Jackie is an antitrust partner in the firm’s Washington, D.C. office. Her practice includes representation of corporate clients in connection with domestic and international mergers and acquisitions, as well as antitrust counseling and other non-merger matters. She regularly appears before the FTC, the DOJ and numerous foreign antitrust enforcement agencies.

Jackie has extensive experience counseling clients through the HSR merger review process, including advocating before the agencies, responding to second requests and coordinating antitrust defense strategies in countries around the world. Her clients span a broad range of industries, including an array of high-tech industries, pharmaceuticals, medical devices, life sciences, automotive parts, consumer and food products, computer and data storage, music recording and publishing, book and magazine publishing, industrial equipment, retail including Internet sales and distribution, and aerospace and defense.

Jackie is recognized as a leading practitioner by Chambers USA, Best Lawyers in America, Who’s Who, Euromoney's Guide to the World's Leading Competition & Antitrust Lawyers and Washington DC Super Lawyers' Top 50 Women.

Jackie is active in the antitrust bar. She formerly served as a vice-chair of the ABA Antitrust Section’s Healthcare and Pharmaceuticals Committee and is co-editor of the ABA Antitrust Section’s book entitled Antitrust Aspects of the Pharmaceutical Industry (2nd). She has also chaired the Section’s flagship Merger Workshop.


  • Horizon Therapeutics in its $28 billion acquisition by Amgen, the third-largest all-cash transaction in biotech history. After an extensive second request investigation, FTC filed suit in May 2023 seeking to block the proposed transaction on the novel theory that it would allow Amgen to leverage its portfolio of “blockbuster” medicines to “entrench the monopoly positions” of two Horizon rare disease medicines. The Horizon/Amgen matter was the FTC’s first litigated challenge to a pharmaceutical merger in more than a decade. Shortly before the PI hearing, the FTC/state AGs announced that they would end their challenge to the deal in what The Wall Street Journal described as a “rare instance” of the FTC “throwing in the towel on litigation.” The FTC settlement not only marks a rare occasion for FTC to settle, but it is the only “behavioral remedy” that the FTC has accepted in the past 8 years.*
  • One Medical in its $3.9 billion sale to Amazon, a transaction closing without remedies after an extensive investigation; Jackie previously represented One Medical in its $2.1 billion acquisition of Iora Health to expand its member-based, technology-powered primary care model to every stage of life.*
  • Intersect ENT, a supplier of drug-eluting stents, in its $1.1 billion sale to Medtronic, achieving unanimous clearance from the FTC after nine-month investigation and divestiture of its ear, nose and throat (ENT) navigation and balloon sinuplasty businesses.*
  • Finicity Corporation, a leading provider of real-time access to financial data and insights, in its $985 million sale to MasterCard, achieving unconditional clearance from DOJ following an extensive second request investigation.*
  • Horizon Therapeutics in its $3 billion acquisition of Viela Bio, a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for autoimmune and severe inflammatory diseases; Horizon in a series of other transactions including acquisition of Hyperion Therapeutics for $1.1 billion, rare disease pharma company Raptor Pharmaceutical in a cash tender offer for approximately $800 million and acquisition of orphan disease drug-maker Crealta Holdings for $510 million in cash, and River Vision for $145 million plus earn-out.*
  • Arena Pharmaceuticals, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases, in its $6.7 billion sale to Pfizer.*
  • Travere Therapeutics in its $445 million sale of bile acid portfolio to Mirum.*
  • Vir Biotechnology, a clinical-stage immunology company focused on treating and preventing serious infectious diseases, on its collaboration with GSK directed at developing antibody candidates for COVID-19.*
  • VelosBio, clinical-stage biopharmaceutical company developing first-in-class therapies targeting ROR1, in its sale to Merck for $2.75 billion.*
  • Clarabridge in its $1.125 billion sale to SAP/Qualtrics.*
  • Baylis in its $1.7 billion sale to Boston Scientific.*
  • Zipwhip, a leading business-texting platform, in its sale to Twilio for $850 million.*
  • Omniome, a biotechnology company developing a DNA sequencing platform capable of delivering high sequencing accuracy, in its sale to Pacific Biosciences for $800 million.*
  • Tilray in its combination with Aphria to create the largest global cannabis company.*
  • MIRROR on its agreement to sell to lululemon athletica for $500 million.*
  • Portola Pharmaceuticals on its agreement to sell to Alexion Pharmaceuticals for $1.41 billion.*
  • Companion Medical, a developer of an insulin delivery system, on its agreement to sell to Medtronic, a global leader in medical technology.*
  • Forty Seven in its sale to Gilead for $4.9 billion, strengthening Gilead’s immuno-oncology research and development portfolio.*
  • Tableau in its $15.7 billion acquisition by Salesforce, combining the world’s #1 CRM and #1 analytics platform.*
  • Synthorx in its $2.5 billion sale to Sanofi, supplementing Sanofi’s pipeline in oncology and immuno-oncology.*
  • Ellie Mae, a cloud-based platform provider for the mortgage finance industry, in its sale to Thoma Bravo for approximately $3.7 billion.*
  • MINDBODY in its sale to Vista Equity Partners for $1.9 billion.*
  • Immune Design in its sale to Merck for $300 million.*
  • Medivation in its sale to Pfizer for approximately $14 billion.*
  • BroadSoft Corporation, a leading unified communications as a service (UcaaS) provider, in its $1.9 billion acquisition by Cisco Systems, Inc., a rival UcaaS provider.*
  • Rockwell Automation in the formation of 50/50 joint venture called Sensia with Schlumberger, for oilfield services which was reported in 14 countries around the world.
  • iCardiac in its acquisition by ERT, expanding ERT’s portfolio of centralized cardiac safety and respiratory laboratory solutions.*
  • Dollar Shave Club (DSC) on its sale to Unilever.*
  • Alarm.com Holdings, Inc. in its acquisition of the Connect and Piper business units from Icontrol Networks.*
  • NetScout Systems, Inc., a provider of performance analytics and operational intelligence solutions for telecommunications service provider and enterprise customers, in obtaining unconditional DOJ clearance of NetScout's proposed $2.6 billion acquisition of the Communications Business of Danaher Corporation. *
  • Bertelsmann in numerous matters including DOJ clearance of Random House's proposed book publishing venture to combine with Penguin; Acquisition of BMG Rights Management interests from KKR (music publishing); FTC clearance of the SonyBMG joint venture (recorded music); DOJ clearance of $2.1 billion divestiture of BMG Music Publishing Group to Vivendi SA.*
  • Volcano Corp. in the acquisition of its catheter-based imaging and measurement solution for cardiovascular application business by Royal Phillips for $1.2 billion, which required regulatory filings in Europe and Asia.*
  • Numerous non-public FTC investigations of various clients into pharmaceutical pricing practices.*
  • Snyder's-Lance, Inc. in obtaining FTC clearance in its acquisition of Snack Factory/Pretzel Crisps. Also represented Snyder's of Hanover and Lance in achieving FTC clearance in connection with their merger, creating second-largest salty snack company in the US.*

*Experience prior to joining Ropes & Gray

Areas of Practice